Future Science Group
Browse
Supplementary materials.docx (234.73 kB)

Supplementary materials: Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma.docx

Download (234.73 kB)
dataset
posted on 2021-12-09, 09:19 authored by Tanja Podkonjak, Holly Cranmer, Julia Scarisbrick, Grant McCarthy, Cameron Lilley, Lung-I Cheng

Table A1. Clinical Inputs.

Table A2. Cost Inputs.

Table A3: Resource utilization.

Table A4. Utility inputs.
Figure A1. Probabilistic sensitivity analysis scatterplot.

Funding

Funded by Takeda Pharmaceuticals International Co.

History

Usage metrics

    Journal of Comparative Effectiveness Research

    Categories

    Keywords

    brentuximabcost-effectivenesscutaneous T-cell lymphomavedotinCancer Therapy (excl. Chemotherapy and Radiation Therapy)

    Licence

    CC BY-NC-ND 4.0

    Exports